Preferred Stock Channel
Market News Video Self Directed Investor The Warren Buffetts Next Door Stock message boards
Quotes delayed 20 minutes


Hold (2.00 out of 4)
6th percentile
(ranked lower than approx. 94% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
www.valueforum.com/7/
Free Preferred Stock Newsletter
Gain access to weekly reports with featured preferred stock screens, new preferred stock offerings, and more.

Slideshow Preferred Stock Offerings

By Preferred Stock Channel Staff, updated Thursday, March 23, 12:13 PM

Slide #320. Cell Therapeutics, Inc. Preferred Stock Offering

Company: Cell Therapeutics, Inc. (NASDAQ:CTIC)
$Amount Offered: $60,000,000
Date of Pricing: 10/5/2012
Price Per Share: $1,000
Preferred Stock Offering Details: Cell Therapeutics, Inc. announced the pricing of an underwritten public offering of 60,000 shares of its Series 17 Preferred Stock, offered at a price to the public of $1,000 per share of Series 17 Preferred Stock (the "Offering"). Each share of Series 17 Preferred Stock is convertible at the option of the holder, at any time, into approximately 714 shares of common stock at a conversion price of $1.40 per share of common stock, for a total of approximately 42.9 million shares of common stock. The shares of Series 17 Preferred Stock will automatically convert into shares of common stock in certain circumstances. Shares of the Series 17 Preferred Stock will receive dividends in the same amount as any dividends declared and paid on shares of common stock, but would be entitled to a liquidation preference over the common stock in certain liquidation events. The Series 17 Preferred Stock will have no voting rights on general corporate matters.

CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of therapies covering a range of blood-related cancers. Co. is primarily focused on treatments that target blood-related cancers where there is an unmet medical need. In particular, Co. is primarily focused on commercializing PIXUVRI® (pixantrone) in select countries in the European Union (E.U.), for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL), and evaluating pacritinib for the treatment of adult patients with myelofibrosis. CTI BioPharma, PIXUVRI and Opaxio are Co.'s proprietary marks.
Open the CTIC Page at Preferred Stock Channel »

Name:  CTI BioPharma Corp
Website:  www.celltherapeutics.com
Sector:  Biotechnology
Number of ETFs Holding CTIC:  1 (see which ones)
Total Market Value Held by ETFs:  $25,398
Total Market Capitalization:  $118,000,000
% of Market Cap. Held by ETFs:  0.02%
 

Open the CTIC Page at Preferred Stock Channel (in a new window) »

Top Ten Highest Yielding Preferred Stocks
Feel-Good Income: Socially Responsible Preferreds
Dividend Channel's 25 S.A.F.E. Dividend Stocks
Increasing Payments For Decades

Safer than S.A.F.E: Preferreds of Dividend Channel's
S.A.F.E. Dividend Stocks

Recent Preferred Stock Offerings
Preferred Stocks of Dow Components
Preferred Stocks of S&P 500 Components
Preferred Stocks By Industry
Preferred Stocks Where Insiders Are Buying The Common
High Yield Preferred Stocks
Preferreds Trading At Premiums To Liquidation Preference
Preferreds Trading At Discounts To Liquidation Preference
The Top 10 DividendRank'ed U.S. Stocks
The Top 10 DividendRank'ed Canadian Stocks
Top 25 Broker Analyst Picks of the S&P 500
Stock market game

Preferred Stock Offerings - Slide 320 of 350 | www.PreferredStockChannel.com | Copyright © 2011 - 2017, All Rights Reserved

Nothing in Preferred Stock Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and dividend videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact Preferred Stock Channel; Meet Our Editorial Staff.